

PATENT COOPERATION TREATY

PCT
NOTIFICATION OF ELECTION
(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

Commissioner
US Department of Commerce
United States Patent and Trademark
Office, PCT
2011 South Clark Place Room
CP2/5C24
Arlington, VA 22202
ETATS-UNIS D'AMERIQUE

in its capacity as elected Office

Date of mailing (day/month/year) 22 May 2001 (22.05.01)	To: Commissioner US Department of Commerce United States Patent and Trademark Office, PCT 2011 South Clark Place Room CP2/5C24 Arlington, VA 22202 ETATS-UNIS D'AMERIQUE in its capacity as elected Office
International application No. PCT/SE00/01799	Applicant's or agent's file reference H 2235-1 WO
International filing date (day/month/year) 18 September 2000 (18.09.00)	Priority date (day/month/year) 22 September 1999 (22.09.99)
Applicant FOLESTAD, Staffan et al	

1. The designated Office is hereby notified of its election made:

in the demand filed with the International Preliminary Examining Authority on:

12 April 2001 (12.04.01)

in a notice effecting later election filed with the International Bureau on:

2. The election was

was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO 34, chemin des Colombelettes 1211 Geneva 20, Switzerland Facsimile No.: (41-22) 740.14.35	Authorized officer Claudio Borton Telephone No.: (41-22) 338.83.38
---	--

PATENT COOPERATION TREATY

V9/6470t

PCT

NOTIFICATION OF THE RECORDING
OF A CHANGE(PCT Rule 92bis.1 and
Administrative Instructions, Section 422)Date of mailing (day/month/year)
27 March 2002 (27.03.02)

From the INTERNATIONAL BUREAU

To:

ASTRAZENECA AB
Global Intellectual Property,
Patents
S-151 85 Södertälje
SUÈDEApplicant's or agent's file reference
H 2235-1 WO

IMPORTANT NOTIFICATION

International application No.
PCT/SE00/01799International filing date (day/month/year)
18 September 2000 (18.09.00)

1. The following indications appeared on record concerning:

 the applicant the inventor the agent the common representative

Name and Address

SPARON, Anders
AstraZeneca R & D Mölndal
S-431 83 R & D Mölndal
Sweden

State of Nationality

SE

State of Residence

SE

Telephone No.

Facsimile No.

Teleprinter No.

2. The International Bureau hereby notifies the applicant that the following change has been recorded concerning:

 the person the name the address the nationality the residence

Name and Address

SPAREN, Anders
AstraZeneca R & D Mölndal
S-431 83 R & D Mölndal
Sweden

State of Nationality

SE

State of Residence

SE

Telephone No.

Facsimile No.

Teleprinter No.

3. Further observations, if necessary:

4. A copy of this notification has been sent to:

 the receiving Office

 the designated Offices concerned

 the International Searching Authority

 the elected Offices concerned

 the International Preliminary Examining Authority

 other:
The International Bureau of WIPO
34, chemin des Colombettes
1211 Geneva 20, Switzerland

Authorized officer

Jean-Marie MCADAMS

Facsimile No.: (41-22) 740.14.35

Telephone No.: (41-22) 338.83.38

09167H7G4P

PATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT 18 JAN 2002

12

(PCT Article 36 and Rule 70)

REC'D

WIPO

PCT

Applicant's or agent's file reference A 2235-1 WO	FOR FURTHER ACTION	See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)
International application No. PCT/SE00/01799	International filing date (day/month/year) 18-09-2000	Priority date (day/month/year) 22-09-1999
International Patent Classification (IPC) or national classification and IPC7 G01N 21/35, G01N 33/15, G01N 21/25		
Applicant ASTRAZENECA AB et al		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.

2. This REPORT consists of a total of 3 sheets, including this cover sheet.

This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of _____ sheets.

3. This report contains indications relating to the following items:

- I Basis of the report
- II Priority
- III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- IV Lack of unity of invention
- V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI Certain documents cited
- VII Certain defects in the international application
- VIII Certain observations on the international application

Date of submission of the demand 12-04-2001	Date of completion of this report 18-12-2001
Name and mailing address of the IPEA/SE Patent- och registreringsverket Box 5055 S-102 42 STOCKHOLM Facsimile No. 08-667 72 88	Authorized officer Gordana Ninkovic /itw Telephone No. 08-782 25 00

I. Basis of the report**1. With regard to the elements of the international application:***

the international application as originally filed

the description:

pages _____, as originally filed

pages _____, filed with the demand

pages _____, filed with the letter of _____

the claims:

pages _____, as originally filed

pages _____, as amended (together with any statement) under article 19

pages _____, filed with the demand

pages _____, filed with the letter of _____

the drawings:

pages _____, as originally filed

pages _____, filed with the demand

pages _____, filed with the letter of _____

the sequence listing part of the description:

pages _____, as originally filed

pages _____, filed with the demand

pages _____, filed with the letter of _____

2. With regard to the language, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language _____ which is:

the language of a translation furnished for the purposes of international search (under Rule 23.1(b)).

the language of publication of the international application (under Rule 48.3(b)).

the language of the translation furnished for the purposes of international preliminary examination (under Rules 55.2 and/or 55.3).

3. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

contained in the international application in written form.

filed together with the international application in computer readable form.

furnished subsequently to this Authority in written form.

furnished subsequently to this Authority in computer readable form.

The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.

The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. The amendments have resulted in the cancellation of:

the description, pages _____

the claims, Nos. _____

the drawings, sheet/fig _____

5. This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2 (c)).**

* Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are annexed to this report since they do not contain amendments (Rules 70.16 and 70.17).

** Any replacement sheet containing such amendments must be referred to under item I and annexed to this report.

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/CO0/01799

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**1. Statement**

Novelty (N)	Claims	<u>1-40</u>	YES
	Claims	_____	NO
Inventive step (IS)	Claims	<u>1-40</u>	YES
	Claims	_____	NO
Industrial applicability (IA)	Claims	<u>1-40</u>	YES
	Claims	_____	NO

2. Citations and explanations (Rule 70.7)

Cited documents:

1. EP 0841548 A2 (Lucent Technologies INC.), 13 May 1998
2. US 5760399 A (W.M.Trygstad), 2 June 1998
3. EP 0727671 A2 (AT&T CORP.), 21 August 1996
4. SPIE, Vol.2979, 1997, pages 107-110: "Discrimination between scattering and absorption inhomogeneities using time-resolved transmittance imaging", P.Taroni et al.
5. Journal of the Optical Society of America, Vol.14, No.1/January 1997, pages 235-245: "Photon migration at short times and distances and in cases of strong absorption", D.J.Durian et al.

The documents cited in the International Search Report represent background art.

The invention defined in claims 1 - 40 is not disclosed by any of these documents.

None of the cited documents gives any indication towards the claimed method and apparatus for use in performing a quantitative analysis of a turbid pharmaceutical sample, e.g. a tablet, a capsule or a similar sample forming a pharmaceutical dose. No relevant combination of the cited documents would lead a person skilled in the art to the invention claimed in the claims.

Therefore, the invention defined in claims 1 - 40 is novel and considered to involve an inventive step. It is also considered to be industrially applicable.

PCT

REQUEST

The undersigned requests that the present international application be processed according to the Patent Cooperation Treaty.

For receiving Office use only

International Application No.

International Filing Date

Name of receiving Office and "PCT International Application"

Applicant's or agent's file reference
(if desired) (12 characters maximum) H 2235-1 WO

Box No. I TITLE OF INVENTION

NEW MEASURING TECHNIQUE

Box No. II APPLICANT

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)

AstraZeneca AB
S-151 85 Södertälje
Sweden

This person is also inventor.

Telephone No.

+8 553 260 00

Faximile No.

+8 553 288 20

Teleprinter No.

State (that is, country) of nationality:
SE

State (that is, country) of residence:
SE

This person is applicant all designated States all designated States except the United States of America the United States of America only the States indicated in the Supplemental Box

Box No. III FURTHER APPLICANT(S) AND/OR (FURTHER) INVENTOR(S)

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)

FOLESTAD, Staffan
AstraZeneca R&D Mölndal
S-431 83 Mölndal
Sweden

This person is:

applicant only

applicant and inventor

inventor only (If this check-box is marked, do not fill in below.)

State (that is, country) of nationality:
SE

State (that is, country) of residence:
SE

This person is applicant all designated States all designated States except the United States of America the United States of America only the States indicated in the Supplemental Box

Further applicants and/or (further) inventors are indicated on a continuation sheet.

Box No. IV AGENT OR COMMON REPRESENTATIVE; OR ADDRESS FOR CORRESPONDENCE

The person identified below is hereby/has been appointed to act on behalf of the applicant(s) before the competent International Authorities as: agent common representative

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country.)

Global Intellectual Property, Patents
AstraZeneca AB
S-151 85 Södertälje
Sweden

Telephone No.

+46 8 553 260 00

Faximile No.

+46 8 553 288 20

Teleprinter No.

Address for correspondence: Mark this check-box where no agent or common representative is/has been appointed and the space above is used instead to indicate a special address to which correspondence should be sent.

Continuation of Box No. III FURTHER APPLICANT(S) AND/OR (FURTHER) INVENTOR(S)

If none of the following sub-boxes is used, this sheet should not be included in the request.

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)

JOSEFSON, Mats
AstraZeneca R&D Mölndal
S-431 83 Mölndal
Sweden

This person is:

- applicant only
 applicant and inventor
 inventor only (if this check-box is marked, do not fill in below.)

State (that is, country) of nationality:
SE

State (that is, country) of residence:
SE

This person is applicant for the purposes of: all designated States all designated States except the United States of America the United States of America only the States indicated in the Supplemental Box

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)

SPARÉN, Anders
AstraZeneca R&D Mölndal
S-431 83 Mölndal
Sweden

This person is:

- applicant only
 applicant and inventor
 inventor only (if this check-box is marked, do not fill in below.)

State (that is, country) of nationality:
SE

State (that is, country) of residence:
SE

This person is applicant for the purposes of: all designated States all designated States except the United States of America the United States of America only the States indicated in the Supplemental Box

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)

JOHANSSON, Jonas
AstraZeneca R&D Mölndal
S-431 83 Mölndal
Sweden

This person is:

- applicant only
 applicant and inventor
 inventor only (if this check-box is marked, do not fill in below.)

State (that is, country) of nationality:
SE

State (that is, country) of residence:
SE

This person is applicant for the purposes of: all designated States all designated States except the United States of America the United States of America only the States indicated in the Supplemental Box

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)

This person is:

- applicant only
 applicant and inventor
 inventor only (if this check-box is marked, do not fill in below.)

State (that is, country) of nationality:

State (that is, country) of residence:

This person is applicant for the purposes of: all designated States all designated States except the United States of America the United States of America only the States indicated in the Supplemental Box

Further applicants and/or (further) inventors are indicated on another continuation sheet.

Box No.V DESIGNATION OF STATES

The following designations are hereby made under Rule 4.9(a) (*mark the applicable check-boxes; at least one must be marked*):

Regional Patent

- AP ARIPO Patent:** GH Ghana, GM Gambia, KE Kenya, LS Lesotho, MW Malawi, MZ Mozambique, SD Sudan, SL Sierra Leone, SZ Swaziland, TZ United Republic of Tanzania, UG Uganda, ZW Zimbabwe, and any other State which is a Contracting State of the Harare Protocol and of the PCT
- EA Eurasian Patent:** AM Armenia, AZ Azerbaijan, BY Belarus, KG Kyrgyzstan, KZ Kazakhstan, MD Republic of Moldova, RU Russian Federation, TJ Tajikistan, TM Turkmenistan, and any other State which is a Contracting State of the Eurasian Patent Convention and of the PCT
- EP European Patent:** AT Austria, BE Belgium, CH and LI Switzerland and Liechtenstein, CY Cyprus, DE Germany, DK Denmark, ES Spain, FI Finland, FR France, GB United Kingdom, GR Greece, IE Ireland, IT Italy, LU Luxembourg, MC Monaco, NL Netherlands, PT Portugal, SE Sweden, and any other State which is a Contracting State of the European Patent Convention and of the PCT
- OA OAPI Patent:** BF Burkina Faso, BJ Benin, CF Central African Republic, CG Congo, CI Côte d'Ivoire, CM Cameroon, GA Gabon, GN Guinea, GW Guinea-Bissau, ML Mali, MR Mauritania, NE Niger, SN Senegal, TD Chad, TG Togo, and any other State which is a member State of OAPI and a Contracting State of the PCT (*if other kind of protection or treatment desired, specify on dotted line*)

National Patent (if other kind of protection or treatment desired, specify on dotted line):

- | | |
|--|--|
| <input checked="" type="checkbox"/> AE United Arab Emirates | <input checked="" type="checkbox"/> LC Saint Lucia |
| <input checked="" type="checkbox"/> AG Antigua and Barbuda | <input checked="" type="checkbox"/> LK Sri Lanka |
| <input checked="" type="checkbox"/> AL Albania | <input checked="" type="checkbox"/> LR Liberia |
| <input checked="" type="checkbox"/> AM Armenia | <input checked="" type="checkbox"/> LS Lesotho |
| <input checked="" type="checkbox"/> AT Austria | <input checked="" type="checkbox"/> LT Lithuania |
| <input checked="" type="checkbox"/> AU Australia | <input checked="" type="checkbox"/> LU Luxembourg |
| <input checked="" type="checkbox"/> AZ Azerbaijan | <input checked="" type="checkbox"/> LV Latvia |
| <input checked="" type="checkbox"/> BA Bosnia and Herzegovina | <input checked="" type="checkbox"/> MA Morocco |
| <input checked="" type="checkbox"/> BB Barbados | <input checked="" type="checkbox"/> MD Republic of Moldova |
| <input checked="" type="checkbox"/> BG Bulgaria | <input checked="" type="checkbox"/> MG Madagascar |
| <input checked="" type="checkbox"/> BR Brazil | <input checked="" type="checkbox"/> MK The former Yugoslav Republic of Macedonia |
| <input checked="" type="checkbox"/> BY Belarus | <input checked="" type="checkbox"/> MN Mongolia |
| <input checked="" type="checkbox"/> BZ Belize | <input checked="" type="checkbox"/> MW Malawi |
| <input checked="" type="checkbox"/> CA Canada | <input checked="" type="checkbox"/> MX Mexico |
| <input checked="" type="checkbox"/> CH and LI Switzerland and Liechtenstein | <input checked="" type="checkbox"/> MZ Mozambique |
| <input checked="" type="checkbox"/> CN China | <input checked="" type="checkbox"/> NO Norway |
| <input checked="" type="checkbox"/> CR Costa Rica | <input checked="" type="checkbox"/> NZ New Zealand |
| <input checked="" type="checkbox"/> CU Cuba | <input checked="" type="checkbox"/> PL Poland |
| <input checked="" type="checkbox"/> CZ Czech Republic | <input checked="" type="checkbox"/> PT Portugal |
| <input checked="" type="checkbox"/> DE Germany | <input checked="" type="checkbox"/> RO Romania |
| <input checked="" type="checkbox"/> DK Denmark | <input checked="" type="checkbox"/> RU Russian Federation |
| <input checked="" type="checkbox"/> DM Dominica | <input checked="" type="checkbox"/> SD Sudan |
| <input checked="" type="checkbox"/> DZ Algeria | <input checked="" type="checkbox"/> SE Sweden |
| <input checked="" type="checkbox"/> EE Estonia | <input checked="" type="checkbox"/> SG Singapore |
| <input checked="" type="checkbox"/> ES Spain | <input checked="" type="checkbox"/> SI Slovenia |
| <input checked="" type="checkbox"/> FI Finland | <input checked="" type="checkbox"/> SK Slovakia |
| <input checked="" type="checkbox"/> GB United Kingdom | <input checked="" type="checkbox"/> SL Sierra Leone |
| <input checked="" type="checkbox"/> GD Grenada | <input checked="" type="checkbox"/> TJ Tajikistan |
| <input checked="" type="checkbox"/> GE Georgia | <input checked="" type="checkbox"/> TM Turkmenistan |
| <input checked="" type="checkbox"/> GH Ghana | <input checked="" type="checkbox"/> TR Turkey |
| <input checked="" type="checkbox"/> GM Gambia | <input checked="" type="checkbox"/> TT Trinidad and Tobago |
| <input checked="" type="checkbox"/> HR Croatia | <input checked="" type="checkbox"/> TZ United Republic of Tanzania |
| <input checked="" type="checkbox"/> HU Hungary | <input checked="" type="checkbox"/> UA Ukraine |
| <input checked="" type="checkbox"/> ID Indonesia | <input checked="" type="checkbox"/> UG Uganda |
| <input checked="" type="checkbox"/> IL Israel | <input checked="" type="checkbox"/> US United States of America |
| <input checked="" type="checkbox"/> IN India | <input checked="" type="checkbox"/> UZ Uzbekistan |
| <input checked="" type="checkbox"/> IS Iceland | <input checked="" type="checkbox"/> VN Viet Nam |
| <input checked="" type="checkbox"/> JP Japan | <input checked="" type="checkbox"/> YU Yugoslavia |
| <input checked="" type="checkbox"/> KE Kenya | <input checked="" type="checkbox"/> ZA South Africa |
| <input checked="" type="checkbox"/> KG Kyrgyzstan | <input checked="" type="checkbox"/> ZW Zimbabwe |
| <input checked="" type="checkbox"/> KP Democratic People's Republic of Korea | |
| <input checked="" type="checkbox"/> KR Republic of Korea | |
| <input checked="" type="checkbox"/> KZ Kazakhstan | |

Check-box reserved for designating States which have become party to the PCT after issuance of this sheet:

Precautionary Designation Statement: In addition to the designations made above, the applicant also makes under Rule 4.9(b) all other designations which would be permitted under the PCT except any designation(s) indicated in the Supplemental Box as being excluded from the scope of this statement. The applicant declares that those additional designations are subject to confirmation and that any designation which is not confirmed before the expiration of 15 months from the priority date is to be regarded as withdrawn by the applicant at the expiration of that time limit. (*Confirmation (including fees) must reach the receiving Office within the 15-month time limit.*)

Box No. VI PRIORITY CLAIM		<input type="checkbox"/> Further priority claim indicated in the Supplemental Box.		
Filing date of earlier application (day/month/year)	Number of earlier application	Where earlier application is:		
		national application: country	regional application: regional Office	international application: receiving Office
item (1) (22.09.99) 22 September 1999	9903423-3	Sweden		
item (2) <i>22 May 01</i>				
item (3)				

The receiving Office is requested to prepare and transmit to the International Bureau a certified copy of the earlier application(s) (only if the earlier application was filed with the Office which for the purposes of the present international application is the receiving Office) identified above as item(s): (1)

* Where the earlier application is an ARIPO application, it is mandatory to indicate in the Supplemental Box at least one country party to the Paris Convention for the Protection of Industrial Property for which that earlier application was filed (Rule 4.10(b)(ii)). See Supplemental Box.

Box No. VII INTERNATIONAL SEARCHING AUTHORITY

Choice of International Searching Authority (ISA) (if two or more International Searching Authorities are competent to carry out the international search, indicate the Authority chosen; the two-letter code may be used):	Request to use results of earlier search; reference to that search (if an earlier search has been carried out by or requested from the International Searching Authority):		
Date (day/month/year)	Number	Country (or regional Office)	
ISA / SE	20 April 2000	ITS SE99/01261	Sweden

Box No. VIII CHECK LIST; LANGUAGE OF FILING

This international application contains the following number of sheets:	This international application is accompanied by the item(s) marked below:	
request : 4	1. <input checked="" type="checkbox"/> fee calculation sheet	
description (excluding sequence listing part) : 10	2. <input type="checkbox"/> separate signed power of attorney	
claims : 4	3. <input checked="" type="checkbox"/> copy of general power of attorney; reference number, if any: GF 2141/ 2000	
abstract : 1	4. <input type="checkbox"/> statement explaining lack of signature	
drawings : 7	5. <input type="checkbox"/> priority document(s) identified in Box No. VI as item(s):	
sequence listing part of description :	6. <input type="checkbox"/> translation of international application into (language):	
Total number of sheets : 26	7. <input type="checkbox"/> separate indications concerning deposited microorganism or other biological material	
	8. <input type="checkbox"/> nucleotide and/or amino acid sequence listing in computer readable form	
	9. <input checked="" type="checkbox"/> other (specify): ITS Report SE99/01261	

Figure of the drawings which should accompany the abstract: 1 Language of filing of the international application: English

Box No. IX SIGNATURE OF APPLICANT OR AGENT

Next to each signature, indicate the name of the person signing and the capacity in which the person signs (if such capacity is not obvious from reading the request).

Södertälje, 18 September 2000

Eva Selin

Eva Selin
Global Intellectual Property, Patents, AstraZeneca AB

For receiving Office use only		
1. Date of actual receipt of the purported international application:	2. Drawings:	
3. Corrected date of actual receipt due to later but timely received papers or drawings completing the purported international application:	<input type="checkbox"/> received: <input type="checkbox"/> not received:	
4. Date of timely receipt of the required corrections under PCT Article 11(2):		
5. International Searching Authority (if two or more are competent): ISA /	6. <input type="checkbox"/> Transmittal of search copy delayed until search fee is paid.	

For International Bureau use only

Date of receipt of the record copy by the International Bureau:

91674764
580

(12) INTERNATIONAL APPL

ON PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
29 March 2001 (29.03.2001)

PCT

(10) International Publication Number
WO 01/22063 A1

(51) International Patent Classification⁷: **G01N 21/35**, (74) Agent: ASTRAZENECA AB; Global Intellectual Property, Patents, S-151 85 Södertälje (SE).

(21) International Application Number: **PCT/SE00/01799**

(22) International Filing Date:

18 September 2000 (18.09.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data: *22 Mar 02/30 m03*
9903423-3 22 September 1999 (22.09.1999) SE

(71) Applicant (for all designated States except US): ASTRAZENECA AB [SE/SE]; S-151 85 Södertälje (SE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): *✓FOLESTAD, Staffan [SE/SE]; AstraZeneca R & D Mölndal, S-431 83 Mölndal (SE); JOSEFSON, Mats [SE/SE]; AstraZeneca R & D Mölndal, S-431 83 Mölndal (SE); SPARON, Anders [SE/SE]; AstraZeneca R & D Mölndal, S-431 83 R & D Mölndal (SE); JOHANSSON, Jonas [SE/SE]; AstraZeneca R & D Mölndal, S-431 83 Mölndal (SE).*

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.


(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

With international search report.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: METHOD AND APPARATUS FOR SPECTROMETRIC ANALYSIS OF TURBID, PHARMACEUTICAL SAMPLES



WO 01/22063 A1

(57) Abstract: The present invention relates to a method and an apparatus for use in performing a quantitative analysis of a turbid pharmaceutical sample, e.g. a tablet, a capsule or a similar sample forming a pharmaceutical dose. A pharmaceutical, turbid sample (24) is irradiated with an excitation beam (20) of radiation, e.g. near infrared radiation. The intensity of emitted radiation (30) from the sample (24) is detected as a function of both the wavelength of the emitted radiation and the photon propagation time through said sample (24). Optionally, the intensity of the emitted radiation (30) from the sample (24) is also detected in a spatially resolved manner.

Method and apparatus for spectrometric analysis of turbid, pharmaceutical samples.

Field of invention

The present invention relates to a method of analysing a turbid pharmaceutical sample, e.g. 5 a tablet, a capsule - especially a multiple unit pellet system (MUPS) tablet or capsule - or a similar sample forming a pharmaceutical dose. The invention also relates to an apparatus for performing such a method.

The present invention can optionally be combined with the invention and the spectrometric methods and set-ups as disclosed in applicant's copending International patent application 10 WO99/49312, filed before the present application but unpublished on the priority date of the present application. Especially, the present invention can be combined with the technique disclosed therein for irradiating two opposite surfaces of an analysed sample, in order to obtain signals representative of the three-dimensional distribution of at least one component in the sample. The content of this International patent application is hereby 15 incorporated by reference.

Background of the invention

Non-invasive, non-destructible analysis of whole tablets can be carried out by means of near-infrared (NIR) or Raman spectrometry. Today, NIR spectroscopy is a recognised 20 technique for performing a fast analysis of compounds. The common feature of both these techniques is that they utilise light in the NIR wavelength region (700-2500 nm, specifically 700-1500 nm) where pharmaceutical tablets are relatively transparent (low molar absorptivity). That is, light can in this region penetrate compressed powders several mm:s why information on the content can be obtained emanating from the bulk of the 25 tablet and not only from the surface. A practical advantage of using NIR radiation is that diode lasers can be used.

One example of such an analysis is described in US 5 760 399, assigned to Foss NIRsystems Inc. This document discloses an instrument for performing a NIR spectrographic transmission measurement of a pharmaceutical tablet. This instrument is, 30 however, capable of providing only limited information as to the content of a sample, typically the quantity of a particular component in a sample. This prior-art instrument cannot provide detailed information of, for example, the three-dimensional distribution of

one or more components in a sample. The technical background on which this limitation is based will be further discussed in connection with the description of the present invention.

The prior art also includes a significant amount of methods for optical imaging of human tissues, in particular for detecting disturbances of homogeneity, such as the presence of a 5 tumour in a human tissue. These methods are generally qualitative measurements, not quantitative, in the sense that they primarily focus on determining the presence and the location of an inhomogeneity. These prior-art methods are not suitable for performing a quantitative analysis on pharmaceutical, turbid samples, such as tablets and capsules, in order to determine e.g. content and structural parameters.

10

Summary of the invention

According to a first aspect of the invention there is provided a method for use in quantitative analysis of a turbid, pharmaceutical sample, in particular a pharmaceutical tablet, capsule of an equivalent pharmaceutical dose.

15 According to the invention, the method comprises the following steps:

- providing an excitation beam of radiation;
- irradiating a pharmaceutical, turbid sample with said excitation beam of radiation; and
- measuring the intensity of emitted radiation from the thus irradiated sample as a function of both the wavelength of the emitted radiation and the photon propagation time through said sample.

20

The invention is based on the following principles. A sample to be analysed by a spectrometric transmission and/or reflection measurement presents a number of so called optical properties. These optical properties are (i) the absorption coefficient, (ii) the scattering coefficient and (iii) the scattering anisotropy. Thus, when the photons of the 25 excitation beam propagate through the turbid sample – in transmission and/or reflection mode - they are influenced by these optical properties and, as a result, subjected to both absorption and scattering. Photons that by coincidence travel along an essentially straight path through the sample and thus do not experience any appreciable scattering will exit the sample with a relatively short time delay. Photons that are directly reflected on the 30 irradiated surface will also present a relatively short time delay, in the case of measurements on reflected light. On the other hand, highly scattered photons (transmitted and/or reflected) exit with a substantial time delay. This means that all these emitted

photons – presenting different propagation times - mediate complementary information about the sample.

In a conventional steady state (no time-resolution) measurement, some of that complementary information is added together since the emitted light is captured by a time-integrated detection. Accordingly, the complementary information is lost in a conventional technique. For instance, a decrease in the registered light intensity may be caused by an increase in the sample absorption coefficient, but it may also be caused by a change in the sample scattering coefficient. However, the information about the actual cause is hidden, since all the emitted light has been time-integrated.

- According to the invention and in contrast to such prior-art NIR spectroscopy with time-integrated intensity detection, the intensity of the emitted radiation from the sample is measured both as a function of the wavelength and as a function of the photon propagation time through said sample. Thus, the inventive method can be said to be both wavelength-resolved and time-resolved. It is important to note that the method is time-resolved in the sense that it provides information about the kinetics of the radiation interaction with the sample. Thus, in this context, the term "time resolved" means "photon propagation time resolved". In other words, the time resolution used in the invention is in a time scale which corresponds to the photon propagation time in the sample (i.e. the photon transit time from the source to the detector) and which, as a consequence, makes it possible to avoid time-integrating the information relating to different photon propagation times. As an illustrative example, the transit time for the photons may be in the order of 0,1-2 ns. Especially, the term "time resolved" is not related to a time period necessary for performing a spatial scanning, which is the case in some prior-art NIR-techniques where "time resolution" is used.
- As a result of not time-integrating the radiation (and thereby "hiding" a lot of information) as done in the prior art, but instead time resolving the information from the excitation of the sample in combination with wavelength resolving the information, the invention makes it possible to establish quantitative analytical parameters of the sample, such as content, concentration, structure, homogeneity, etc.
- Both the transmitted radiation and the reflected radiation from the irradiated sample comprise photons with different time delay. Accordingly, the time-resolved and wavelength resolved detection may be performed on transmitted radiation only, reflected radiation only, as well as a combination of transmitted and reflected radiation.

The excitation beam of radiation used in the present invention may include infrared radiation, especially near infrared (NIR) radiation of in the range corresponding to wavelengths of from about 700 to about 1700 nm, particularly from 700 to 1300 nm. However, the excitation beam of radiation may also include visible light (400 to 700 nm) and UV radiation. In this connection, it should also be stated that the term "excitation" should be interpreted as meaning "illumination", i.e. no chemical excitation of the sample is necessary.

Preferably, the step of measuring the intensity as a function of photon propagation time is performed in time-synchronism with the excitation of the sample. In a first preferred embodiment, this time synchronism is implemented by using a pulsed excitation beam, presenting a pulse train of short excitation pulses, wherein each excitation pulse triggers the intensity measurement. To this end, a pulsed laser system or laser diodes can be used. This technique makes it possible to perform a photon propagation time-resolved measurement of the emitted intensity (transmitted and/or reflected) for each given excitation pulse, during the time period up to the subsequent excitation pulse.

In order to avoid any undesired interference between the intensity measurements relating to two subsequent excitation pulses, such excitation pulses should have a pulse length short enough in relation to the photon propagation time in the sample and, preferably, much shorter than the photon propagation time.

To summarise, in this embodiment of the invention the intensity detection of the emitted radiation associated with a given excitation pulse is time-synchronised with this pulse, and the detection of the emitted light from one pulse is completed before the next pulse.

The data evaluation can be done in different ways. By defining the boundary conditions and the optical geometry of the set-up, iterative methods such as Monte Carlo simulations can be utilised to calculate the optical properties of the sample and indirectly content and structural parameters. Alternatively, a multivariate calibration can be used for a direct extraction of such parameters. In multivariate calibration, measured data is utilised to establish an empirical mathematical relationship to the analytical parameter of interest, such as the content or structure of a pharmaceutical substance. When new measurements are performed, the model can be used to predict the analytical parameters of the unknown sample.

In an alternative embodiment the radiation source is intensity modulated in time. Then, frequency domain spectroscopy can be used for determining phase shift and/or modulation

depth of the emitted radiation from the sample. Thus, the phase and/or modulation depth of the emitted sample radiation is compared with those of the excitation radiation. That information can be used to extract information about the time delay of the radiation in the sample. It should be noted that such a frequency domain spectroscopy is also a "time-resolved" technique according to the invention, since it also provides information about the kinetics of the photon interaction with the sample. With similar mathematical procedures as above, the same quantitative analytical information can be extracted.

A pulsed excitation beam according to the first embodiment, and an intensity modulated excitation beam according to the second embodiment, share the common feature that they make it possible to identify – in said excitation beam - a specific "excitation time point" which can be used to trigger the detection of the emitted radiation from the sample, i.e. to time-synchronise the time-resolved detection with the excitation of the sample. This can be performed by letting the pulsed or modulated beam trigger a photodetector or the equivalent, which in its turn triggers the detection unit via suitable time-control circuitry.

The time-resolved detection may be implemented by the use of a time-resolved detector, such as a streak camera. It may also be implemented by the use of a time-gated system, by which the detection of emitted radiation is performed during a limited number of very short time slices instead of the full time course. The time length of each such time slice is only a fraction of the detection time period during which the time resolved detection is performed for each excitation. By measuring several such "time slices" a coarse time resolution is achieved. An attractive alternative is to measure wavelength resolved spectra at two such time gates, prompt light and delayed light. Furthermore, time-resolved data may be recorded by means of other time-resolved equipment, transient digitizers or equivalent.

The wavelength-resolved detection may be implemented in many different, conventional ways. It may be implemented by the use of one or more single-channel detectors for selecting one or more wavelengths, such as ultrafast photo diodes, photomultipliers, etc, or by the use of a multi-channel detector, such as a microchannel plates or a streak camera. Use can be made of light dispersive systems, such as (i) a spectrometer, (ii) a wavelength dependent beam splitter,(iii) a non-wavelength dependent beam splitter in combination with a plurality of filters for filtering each of respective components for providing radiation of different wavelength or wavelength band, (iv) a prism array or a lens system separating the emitted radiation from the sample into a plurality of components in combination with a plurality of filters, etc.

In accordance with a further aspect of the invention, there is also provided an apparatus for performing the inventive method, said apparatus having the features as defined in the enclosed claims.

The above and other features and advantages of the invention are defined in the claims and described in greater detail below with reference to the accompanying drawings, which illustrate preferred embodiments.

Description of the drawings

Fig. 1a illustrates a set-up for performing a time-resolved and wavelength-resolved analysis according to the invention.

Fig. 1b illustrates an embodiment where the excitation and the collection of emitted light are performed at the irradiation side only of the sample.

Fig. 2 illustrates functional components for implementing the present invention.

Fig. 3a is a streak camera image, illustrating an experimental result of a wave-length-resolved and time-resolved tablet transmission measurement according to the invention.

Fig. 3b is a 3D plot of the streak camera image in Fig. 3a.

Fig. 4a is a streak camera image, illustrating an experimental result of a time-resolved tablet transmission measurement according to the invention, in combination with spatial resolution.

Fig. 4b is a 3D plot of the streak camera image in Fig. 4a.

Fig. 5 is a diagram illustrating experimental results from transmission measurements on two different tablet samples.

Description of preferred embodiments

Referring now to Fig. 1a, an apparatus according to a first embodiment for performing a time-resolved analysis according to the invention comprises a Ti:sapphire laser 10 pumped by an argon ion laser 12. The laser beam 14 thereby generated is amplified by a

neodymium YAG amplifier stage 16 into an amplified laser beam 18. In order to create an excitation beam 20 of "white" light, the laser beam 18 is passed through a water filled cuvette 22 via a mirror M1 and a first lens system L1.

A sample to be analysed is schematically illustrated at reference numeral 24 and comprises a front surface 26 and a back surface 28. The sample 24 is temporarily fixed in a sample positioning unit (not shown). The excitation laser beam 20 is focused onto the front surface 26 of sample 24 via a lens system L2/L3 and mirrors M2-M4. On the opposite side of sample 24, the transmitted laser beam 30 is collected from the backside by lens system L4/L5 and focused into a spectrometer 32. In the illustrated set-up, the sample 24 may be a pharmaceutical, solid tablet having a diameter of e.g. 9 mm. The excitation beam 20 may be focused on a spot of about 1 mm. In other embodiments, the excitation beam may be focused on the whole sample, or scanned over the sample.

As schematically illustrated in Fig. 1a, the excitation beam 20 in this embodiment is time-pulsed into a pulse train of short, repetitive excitation pulses P. The pulse length of each excitation pulse P is short enough and the time spacing between two consecutive excitation pulses P is long enough in relation to the transit time of the beam (i.e. in relation to the time taken for each pulse to be completely measured in time), such that any interference is avoided between the detected light from one given excitation pulse P_n and the detected light from the next excitation pulse P_{n+1} . Thereby, it is possible to perform a time-resolved measurement on the radiation from one excitation pulse P at a time.

From the spectrometer 32, the detected light beam 33 is passed via lens system L6/L7 to a time-resolved detection unit, which in this embodiment is implemented as a streak camera 34. The streak camera 34 used in an experimental set-up according to Fig. 1 was a Hamamatsu Streak Camera Model C5680. Specifically, the streak camera 34 has an entrance slit (not shown) onto which the detected light beam 33 from the spectrometer 32 is focused. It should be noted that only a fraction of the light emitted from the sample is actually collected in the spectrometer 32 and, thereby, in the detection unit 34. As a result of passing through the spectrometer 32, the emitted radiation 30 from the sample 24 is spectrally divided in space, such that radiation received by the streak camera 34 presents a wavelength distribution along the entrance slit.

The incecent photons at the slit are converted by the streak camera into photoelectrons and accelerated in a path between pairs of deflection plates (not shown). Thereby, the photoelectrons are swept along an axis onto a microchannel plate inside the camera, such that the time axis of the incident photons is converted into a spatial axis on said

microchannel plate. Thereby, the time in which the photons reached the streak camera and the intensity can be determined by the position and the luminance of the streak image. The wavelength-resolution is obtained along the other axis. The photoelectron image is read out by a CCD device 36, which is optically coupled to the streak camera 34. The data collected by the CCD device 36 is coupled to an analysing unit 38, schematically illustrated as a computer and a monitor.

In the set-up in fig. 1a, the intensity of the emitted light is measured as a function of time in time-synchronism with each excitation of the sample. This means that the detection unit comprising the streak camera 34 and the associated CCD device 36 is time-synchronised with the repetitive excitation pulses P. This time-synchronism is accomplished as follows: each excitation pulse P of the laser beam 14 triggers a photodetector 42 or the equivalent via an optical element 40. An output signal 43 from the photodetector 42 is passed via a delay generator 44 to a trig unit 46, providing trig pulses to the streak camera 34. In this manner, the photon detection operation of the streak camera is activated and de-activated at exact predetermined points of time after the generation of each excitation pulse P.

As mentioned above, the evaluation and analyse of the collected, time-resolved information can be done in different ways. As schematically illustrated in Fig. 1, the collected data information from each excitation is transferred from the streak camera 34 and the CCD device 36 to a computer 38 for evaluation of the information. Monte Carlo simulations, multivariate calibrations, etc as mentioned in the introductory part of this application can be utilised in order to calculate the optical properties of the sample and, indirectly, content and structural parameters of the sample 24.

In the embodiment shown in Fig. 1b, it is the transmitted radiation – the beam 30 – which is detected in a time-resolved manner. However, the invention can also be implemented by detecting the radiation reflected from the sample. Fig. 1b schematically illustrates how an excitation beam 20' corresponding to excitation beam 20 in Fig. 1 is focused via a lens L3' onto the front surface 26 of a sample 24. The photons of each excitation pulse will be reflected both as directly reflected photons from the front surface 26 as well as diffusely backscattered photons with more or less time delay. This directly reflected radiation as well as the diffusely backscattered radiation is collected by a lens L4' into a detection beam 30', corresponding to detection beam 30 in Fig. 1.

As stated above, it is possible to combine the embodiments illustrated in Figs 1a and 1b into one single embodiment, where both transmitted and backscattered light is detected and analysed in a time-resolved and wavelength-resolved manner according to the invention.

Fig. 2 schematically discloses the main functional components in an embodiment for implementing the inventive method, including a radiation generation unit 100 (components 10, 12 and 16 in Fig. 1a), a sample positioning unit 102, one or more wavelength dispersive/selective elements 104 (component 32 in Fig. 1a), one or more detector units 106 (components 34 and 36) in Fig. 1a) and an analysing unit 108 (component 38 in Fig. 1a).

The water filled cuvette 22 producing white laser light in combination with the spectrometer 32 acting as a wavelength-dispersive element makes it possible to collect data that is both wavelength-resolved and time-resolved. Figs 3a and 3b illustrate the experimental result of such a detection. It should be noted that the time scale in both Fig. 3a and Fig. 3b illustrate the intensity variation over time for one pulse only, although the actual data used for producing these figures is based on accumulated data from many readings. The time axis in Fig. 3a and 3b is in nano second scale.

Fig. 3a illustrates a streak camera image pasted into a time-wavelength diagram, the light portions correspond to high intensity values. The left part of the image corresponds to detected photons having a relatively short time delay, whereas the right part of the image corresponds to photons with a relatively long delay time.

The 3D plot in Fig. 3b corresponds to the image in Fig. 3a. This 3D plot clearly illustrates how the time-resolved spectroscopy according to the invention results in an intensity measurement as a function of both wavelength and photon propagation time. This 3D plot also clearly illustrate that the total information content as obtained by the present invention is significantly greater than the information obtainable with a conventional time-integrated detection.

In Fig. 3b, for each wavelength (such as for the wavelengths λ_1 and λ_2 as identified in Fig. 3b) there is a multitude of timely spaced intensity readings. Thus, for each wavelength it is possible to obtain a full curve of emitted (transmitted and/or reflected) intensity vs. propagation time. The form of these "time profiles" shown in Fig. 3b is dependent on the relation between the optical properties of the analysed sample. With such a time-resolved and wavelength-resolved spectroscopy, it is possible to obtain information for describing the light interaction with the sample. As an example, this provides the basis for determining an analyte concentration in a sample that is proportional to the absorption coefficient but not related to the scattering. As another example, one might want to measure an analytical quantity that correlates to the scattering properties of the sample instead.

As illustrated by the dashed lines t1 and t2 in Fig. 3b, it is also possible to evaluate the emitted light by detecting the intensity during fixed time slices. This would give a more coarse time resolution. In one embodiment, wavelength-resolved spectra are measured at two time gates only – one for "prompt" light and one for "delayed" light.

- 5 The intensity-time diagram in Fig. 5 illustrates two experimental, time-resolved results from measurements on two different tablets. By selecting suitable time gates where the difference is substantial, one can easily distinguish different tablets from each other.

10 As an alternative to the set-up illustrated in Figs. 1a and 1b, instead of using the water cuvette 20 in combination with the spectrometer 32, it is possible to use wavelength selective light sources, such as diode lasers. On the detector side, wavelength selective detectors, such combinations of filters and detector diodes, can be used for each wavelength.

15 It is possible to combine the invention with a spatial-resolved intensity detection on the emitted light from the sample. In this context, the term "spatial resolved" refers to a spatial resolution obtained for each excitation pulse. Especially, "spatial-resolved" does not refer to a spatial resolution based on a scanning in time of the excitation beam in relation to the sample. As an illustrative example, by removing the water cuvette 22 and the spectrometer 32 in the Fig. 1a set-up, the light focused on the entrance slit of the streak camera would be spatial resolved along the slit, corresponding to a "slit" across the sample. A streak camera image obtained by such a set-up is illustrated in Fig. 4a, and a corresponding 3D plot is 20 illustrated in Fig. 4b. In accordance with Figs 3a and 3b discussed above, Figs 4a and 4b represent one pulse only; i.e. the spatial resolution illustrated does not correspond to any scanning of the excitation beam over the sample.

CLAIMS

1. A method for use in quantitative analysis of a turbid, pharmaceutical sample (24), comprising the following steps:

- providing an excitation beam (20) of radiation;
- irradiating a pharmaceutical, turbid sample (24) with said excitation beam (20) of radiation; and
- detecting the intensity of emitted radiation (30) from the sample (24) as a function of both the wavelength of the emitted radiation and the photon propagation time through said sample (24).

10 2. A method as claimed in claim 1, wherein said emitted radiation comprises transmitted radiation (30) from said sample (24).

3. A method as claimed in claim 1, wherein said emitted radiation comprises diffusely reflected radiation (30') from said sample (24).

15 4. A method as claimed in claim 1, wherein said emitted radiation comprises transmitted radiation (30) as well as diffusely reflected radiation (20') from said sample (24).

20 5. A method as claimed in any of claims 1-4, wherein said excitation beam (20) is a pulsed excitation beam presenting a pulse train of excitation pulses (P), and wherein the step of detecting the intensity as a function of the photon propagation time is performed in time synchronism with said excitation pulses (P).

6. A method as claimed in claim 5, wherein said excitation pulses (P) have a pulse length shorter than the photon propagation time.

25 7. A method as claimed in claim 6, wherein said excitation pulses (P) have a pulse length selected short enough in relation to the photon propagation time such that any undesired interference between intensity measurements relating to two subsequent excitation pulses is prevented.

8. A method as claimed in any of claims 1-4, wherein said excitation beam (20) is an intensity modulated excitation beam.

9. A method as claimed in claim 8, wherein the step of detecting the intensity as a function of the photon propagation time is performed by comparing the phase of the intensity modulated excitation beam (20) with the phase of the emitted radiation (30) from the sample (24).

5 10. A method as claimed in claim 8 or 9, wherein the step of detecting the intensity as a function of the photon propagation time is performed by comparing the modulation depth of the intensity modulated excitation beam (20) with the modulation depth of the emitted radiation (30) from the sample (24).

10 11. A method as claimed in any of claims 1-10, wherein said detection of the intensity of emitted radiation (30) from the sample (24) as a function of time is performed by the use of a time-resolved detection unit.

12. A method as claimed in any of claims 1-10, wherein said detection of the intensity of emitted radiation (30) from the sample (24) as a function of time is performed by the use of a phase-resolved detection unit.

15 13. A method as claimed in any of claims 1-10, wherein said detection of the intensity of emitted radiation (30) from the sample (24) as a function of time is performed by the use of a time-gated system.

14. A method as claimed in any of the preceding claims, wherein said step of detecting the intensity further includes a spatial-resolved detection of said intensity.

20 15. A method as claimed in any of the preceding claims, wherein said pharmaceutical, turbid sample is a solid sample (24), in particular a tablet, a capsule, a bulk powder or an equivalent pharmaceutical dose.

25 16. A method as claimed in claim 15, wherein said step of irradiating the sample with said excitation beam comprises the step of irradiating a first surface of the solid sample (24).

17. A method as claimed in claim 15, wherein said step of irradiating the sample with said excitation beam (20) comprises the step of irradiating a first surface and a second surface of the solid sample (24), especially oppositely-directed surfaces.

30 18. A method as claimed in claim 17, wherein the first surface and the second surface of the solid sample are irradiated at different points in time.

19. A method as claimed in any of claims 1-14, wherein said pharmaceutical, turbid sample is a dispersion.

20. A method as claimed in any of the preceding claims, wherein the excitation beam (20) comprises infrared radiation.

5 21. A method as claimed in claim 20, wherein the infrared radiation is in the near infrared radiation (NIR).

22. A method as claimed in claim 21, wherein the radiation has a frequency in the range corresponding to wavelengths of from about 700 to about 1700 nm, particularly from 700 to 1300 nm.

10 23. A method as claimed in any of the preceding claims, wherein the excitation beam (20) comprises visible light.

24. A method as claimed in any of the preceding claims, wherein the excitation beam (20) comprises UV radiation.

15 25. A method for use in an analysis of turbid sample (24), wherein an excitation radiation is directed onto said sample (24) and wherein the intensity of emitted radiation (30) from the thus radiated sample (24) is measured as a function of both wavelength of the emitted radiation (30) and photon propagation time through said sample (24).

26. An apparatus for use in quantitative analysis of a turbid pharmaceutical sample (24), comprising:

- 20 - means (10, 12, 16) for generating an excitation beam (20) of radiation;
- means for positioning a pharmaceutical, turbid sample (24),
- means for focusing said excitation beam (20) onto said sample (24);
- means (32, 34, 36) for detecting the intensity of emitted radiation (30) from the sample (24) as a function of both the wavelength of the emitted radiation and the photon propagation time through said sample (24).

25 27. An apparatus as claimed in claim 26, wherein said means for detecting comprises a time-resolved detection unit (34).

28. An apparatus as claimed in claim 27, wherein said time-resolved detection unit comprises a streak camera (34).

29. An apparatus as claimed in claim 26, wherein said means for detecting comprises a phase-resolved detection unit.

30. An apparatus as claimed in claim 26, wherein said means for detecting comprises a time-gated system.

5 31. An apparatus as claimed in any of claims 26-30, further comprising means for performing a spatial-resolved detection of said intensity.

32. An apparatus as claimed in any of claims 26-31, wherein said pharmaceutical, turbid sample is a solid sample (24), in particular a tablet, a capsule, a bulk powder or an equivalent pharmaceutical dose.

10 33. A apparatus as claimed in any of claims 26-31, wherein said pharmaceutical, turbid sample is a dispersion.

34. An apparatus as claimed in claim 26, wherein the excitation beam (20) comprises infrared radiation.

15 35. An apparatus as claimed in claim 34, wherein the infrared radiation is in the near infrared radiation (NIR).

36. An apparatus as claimed in claim 26, wherein the radiation has a frequency in the range corresponding to wavelengths of from about 700 to about 1700 nm, particularly from 700 to 1300 nm.

20 37. An apparatus as claimed in any of claims 26-36, wherein the excitation beam (20) comprises visible light.

38. An apparatus as claimed in any of claims 26-37, wherein the excitation beam (20) comprises UV radiation.

39. An apparatus as claimed in any of claims 26-38, wherein said means (10, 12, 16) for generating comprises one or more diode lasers.

25 40. An apparatus as claimed in any of claims 26-38, wherein said means (10, 12, 16) for generating comprises an intensity modulated lamp.




FIG. 1a

2/7




FIG. 2




FIG. 1b

3/7




FIG. 3a

4/7




FIG. 3b

5/7




FIG. 4a

6/7




FIG. 4b

7/7




FIG. 5

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 00/01799

A. CLASSIFICATION OF SUBJECT MATTER

IPC7: G01N 21/35, G01N 33/15, G01N 21/25

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC7: G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE, DK, FI, NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0841548 A2 (LUCENT TECHNOLOGIES INC.), 13 May 1998 (13.05.98) --	1-40
A	US 5760399 A (W.M. TRYGSTAD), 2 June 1998 (02.06.98) --	1-40
A	EP 0727671 A2 (AT&T CORP.), 21 August 1996 (21.08.96) --	1-40

 Further documents are listed in the continuation of Box C. See patent family annex.

* Special categories of cited documents:	
"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E" earlier application or patent but published on or after the international filing date	"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

20 December 2000

Date of mailing of the international search report

27-12-2000

Name and mailing address of the ISA/
Swedish Patent Office
Box 5055, S-102 42 STOCKHOLM
Facsimile No. +46 8 666 02 86

Authorized officer

Jonas Andersson/MN
Telephone No. +46 8 782 25 00

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 00/01799

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	Proceedings of the SPIE - The International Society for Optical Engineering, Vol. 2979, 1997, pages 107-110, "discrimination between scattering and absorption inhomogeneities using time-resolved transmittance imaging", P. Taroni et al. --	1-40
A	Journal of the Optical Society of America A, Vol. 14, No. 1/January 1997, pages 235-240, D.J. Durian et al: "Photon migration at short times and distances and in case of strong absorption". -- -----	1-40

INTERNATIONAL SEARCH REPORT
Information on patent family members

04/12/00

International application No.
PCT/SE 00/01799

Patent document cited in search report	Publication date		Patent family member(s)	Publication date
EP 0841548 A2	13/05/98	JP US	10153547 A 5939721 A	09/06/98 17/08/99
US 5760399 A	02/06/98	CA EP JP	2185613 A 0767369 A 9178658 A	03/04/97 09/04/97 11/07/97
EP 0727671 A2	21/08/96	JP US US	8320254 A 5623145 A 5710430 A	03/12/96 22/04/97 20/01/98